ASSET ACQUISITION - Schedule of Total Consideration Transferred Assets Acquired, Liabilities Assumed (Details) - USD ($) $ in Thousands		3 Months Ended	9 Months Ended
	Jul. 01, 2025	Sep. 30, 2025	Sep. 30, 2025	Sep. 30, 2024
Asset Acquisition [Line Items]
Acquired IPR&D			$ 220,963	$ 0
Inozyme Pharma Inc
Asset Acquisition [Line Items]
Cash consideration for outstanding shares	$ 260,424
Cash consideration for equity awards	9,950
Consideration paid to Inozyme	270,374
Repayment of Inozyme debt	49,095
Employee-related incentive payments	2,714
Transaction costs	6,950
Total consideration	329,133
Cash and cash equivalents	43,939
Other assets	10,779
Deferred tax assets	68,697
Other liabilities	(15,245)
Total identifiable assets acquired, net	108,170
Acquired IPR&D	220,963	$ 221,000
Total assets and liabilities	$ 329,133